Crispr Therapeutics AG (CRSP) — Free Cash Flow Generation Index

Latest as of March 2024: 0.99x

Crispr Therapeutics AG (CRSP) has a Free Cash Flow Generation Index of 0.99x as of March 2024. Free cash flow of $109.03 Million represents 1% of operating cash flow ($109.75 Million). See CRSP current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

FCF Generation Index

0.99x
Free Cash Flow / Operating CF

Free Cash Flow

$109.03 Million
USD

Operating Cash Flow

$109.75 Million
USD

Capital Expenditures

$721.00K
USD

Crispr Therapeutics AG Free Cash Flow Generation Index (2015–2021)

Historical FCF Generation Index trend for Crispr Therapeutics AG across 3 annual periods. Explore Crispr Therapeutics AG (CRSP) cash flow to debt to assess how comfortably operating cash covers total debt obligations.

Annual Free Cash Flow Generation for Crispr Therapeutics AG (2015–2021)

Year-by-year Free Cash Flow Generation Index for Crispr Therapeutics AG. For the full company profile including market capitalisation, see Crispr Therapeutics AG stock valuation.

Year FCG Index Free Cash Flow (USD) Operating CF Capital Expenditures YoY Change
2021 0.85x $457.27 Million $538.97 Million $81.70 Million ▼ -3.8%
2019 0.88x $49.99 Million $56.68 Million $6.68 Million ▼ -10.0%
2015 0.98x $58.27 Million $59.43 Million $1.15 Million
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).